GEN Exclusives

More »

GEN News Highlights

More »
Oct 29, 2007

Nventa Issued Patent that Covers Fusion Protein Therapeutics for HPV-related Diseases

  • Nventa Biopharmaceuticals was issued a patent for compositions and methods for inducing or enhancing immune responses to a human papillomavirus (HPV) antigen with or without the use of an adjuvant. The company's CoVal™ HPV protein fusions are being developed to treat patients with HPV-related diseases.

    The patent provides for a method of treating a tumor expressing an HPV antigen through the administration of an effective amount of a composition comprised of an HPV antigen joined or fused to a stress protein, according to Gregory M. McKee, president and CEO of Nventa. This patent provides additional patent exclusivity for HspE7, the Company's investigational therapeutic vaccine, and future HPV fusions through February 2019.

    "The issuance of this patent protecting the use of our HPV CoVal protein fusions to treat HPV-related diseases strengthens our intellectual property portfolio and, we believe, adds further value to our HspE7 program, which is currently in Phase I clinical development," says McKee.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »